Aortic Aneurysm Market Size Worth $4.71 Billion By 2026

The global aortic aneurysm market size is estimated to reach USD 4.71 billion by 2026 registering a CAGR of 8.6%, according to a new report by Grand View Research, Inc. Growing geriatric population in developed countries and rise in the number of tobacco smokers are expected to be the key factors driving the global market. Technological advancements in endovascular surgical procedures will augment the market growth further.

Cases of Abdominal Aortic Aneurysms (AAAs), especially in men aged 65 years and above, surpassed the number of Thoracic Aortic Aneurysm Repair (TAA) by threefold. This has increased the demand for advanced stent-graft systems for AAA. Due to the lack of multiple treatment options and being a complex procedure, TAA procedures are fewer. This offers a lucrative opportunity to the manufacturers for developing advanced products for Thoracic Endovascular Aneurysm Repair (TEVAR).

Companies in the market focus on M&A activities to gain higher market share. For instance, leading companies, such as Medtronic, Endologix, and Terumo, acquired smaller firms to expand their product portfolios and geographical reach. In addition, recent FDA approvals have aided in overall market growth. For example, in 2016, Cook Medical received commercialization rights for its Zenith product line in the U.S market for TEVAR.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/aortic-aneurysm-market

Further key findings from the study suggest:

  • In 2018, AAA segment held the largest share of the global aortic aneurysm market on account of high disease incidences
  • Stent grafts held a major market share, in terms of sales revenue, in 2018, as they have more than 50% share in the overall surgical treatment cost of a patient
  • Endovascular Aortic Aneurysm Repair (EVAR), which includes minimally invasive surgeries, is expected to be the fastest-growing segment in future as it is more efficient than open aneurysm due to fewer postsurgical adverse effects
  • North America held the highest revenue share in 2018 followed by Europe on account of well-established healthcare infrastructure, access to advanced screening and diagnostic tools for AAA, and favorable reimbursement scenario in the region
  • Cook Medical Devices Pvt. Ltd., Medtronic PLC, Lifetech Scientific Corp., and Gore Medical are some of the key companies in the global market

Artificial Intelligence In Healthcare Market Worth $31.3 Billion By 2025

The global artificial intelligence in healthcare market size is expected to reach USD 31.3 billion by 2025, growing at a CAGR 41.5% over a forecast period, according to a new report by Grand View Research, Inc. The rising demand to reduce healthcare costs, increasing adoption of precision medicine, growing importance of big data in healthcare, and declining hardware costs are some factors propelling adoption of AI technology in healthcare industry. Moreover, rise in potential applications of AI-based tools in medical care and growth in venture capital investments are anticipated to aid growth over the forecast period.

Rise in the number of cross-industry collaborations is anticipated to fuel growth. For instance, in March 2018,Microsoft announced partnership with Apollo Hospitals, one of the prominent healthcare systems in India. The partnership was focused on developing and deploying new machine learning models for predicting the risk of developing cardiac diseases and aid doctors in treatment planning. Increase in venture capital funding is a key factor propelling growth of AI start-ups, which is further contributing to market growth.

The adoption of AI in healthcare is increasing, as healthcare providers are focused on enhancing patient care further. The adoption of this technology in healthcare has various benefits, both patients and healthcare providers. AI enables personalized care, based on body constitution and past medical history. Moreover, the shortage of physicians in some countries is anticipated to increase demand for AI in healthcare.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-healthcare-market

Further key findings from the study suggest:

  • In 2018, software solutions held the largest revenue share owing to the development of AI-based software solutions for the healthcare sector
  • Clinical trials held the largest revenue share in 2018, and this can be attributed to the growing focus of pharmaceutical companies on incorporating AI in automation of clinical trial processes.
  • North America held the largest revenue share, owing to high adoption of healthcare IT solutions in the region and availability of well-established healthcare infrastructure
  • Asia Pacific is expected to exhibit the fastest CAGR over the forecast period, owing to growing AI-based start-ups, improving healthcare IT infrastructure, and increasing adoption of advanced technologies.
  • Some key players are IBM Corporation; NVIDIA Corporation, Nuance Communications, Inc.; Microsoft; Intel Corporation; and DeepMind Technologies Limited

Video Game Market Size Worth $398.15 Billion By 2027

The global video game market size is anticipated to reach USD 398.15 billion by 2027, registering a CAGR of 12.9% from 2020 to 2027, according to a new report by Grand View Research, Inc. Technological advancements in hardware and software are anticipated to accelerate the market growth. Video game has emerged as one of the most lucrative industries in the entertainment sector, besides the film and music industries. Continuous advancements in Augmented Reality (AR) and Virtual Reality (VR), have been instrumental in opening up several avenues for the overall gaming market expansion.

The introduction of VR and the immersive gaming experience offered by VR is subsequently boosting the market growth. The adoption of VR headsets is on the rise and is increasingly prompting market players to generate VR content to capitalize on the opportunities created by virtual reality. Mobile phones offer cheaper platforms for gaming and users can turn their smartphones into VR gaming devices with the help of VR peripherals such as Google Cardboard.

Rising penetration of mobile gaming provides substantial opportunities to vendors in the market to develop mobile video games. Vendors are also trying to grab this opportunity by developing their own mobile games or by acquiring mobile video game developers. For instance, in February 2018, Disney Interactive entered into a mobile game agreement with Glu Mobile to develop mobile games based on characters from Disney and Pixar film franchises.

The growth in the development of VR and AR related products, such as Head-Up Displays (HUD) and Head Mounted Displays (HMD), has enhanced the gaming experience, making it more engaging. Vendors are focusing on launching various video game subscription services which allow users to download and play games. For instance, in September 2019 Apple, Inc. introduced Apple Arcade, a game subscription service for desktop and mobiles. The new game subscription service allows users to download and play number of games from App Store that have no in-app purchase or any additional costs by paying one-month subscription fee.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/video-game-market

Further key findings from the study suggest:

  • The mobile segment is projected to gain momentum and expand at the highest CAGR over the forecast period, owing to the increasing smartphone penetration across the globe. The use of tablet phones for an improved viewing and playing experience is further expected to contribute to the growth
  • The online segment is estimated to witness substantial growth over the next eight years, attributed to the increasing broadband penetration and growing online betting, gambling, and social network gaming
  • Asia Pacific is expected register fastest growth over the forecast period. Countries such as China, India, and South Korea are offering lucrative growth opportunities, which can be partly attributed to the growing smartphone and internet penetration in these countries

Contactless Biometrics Technology Market Worth $30.15 Billion By 2027

The global contactless biometrics technology market size is expected to reach USD 30.15 billion by 2027, registering a Compound Annual Growth Rate (CAGR) of 20.3% from 2020 to 2027, according to a new study by Grand View Research, Inc. Rising demand for security and surveillance owing to the increasing threats of terrorist attack and penetration of contactless biometrics solutions in enterprise applications is anticipated to propel the market growth. The demand is steadily increasing amid the COVID-19 outbreak. This pandemic has also influenced various digital businesses, which are now developing facial recognition systems to secure their online platforms.

Rise of digital banking across the globe is a major impetus behind the introduction of voice and facial recognition in banking and financial sector. For instance, in June 2016, Citigroup Inc. introduced voice biometrics to verify customer’s identities. The use of contactless biometrics authentication for banks offers an additional, convenient, and user-friendly way of verifying their customers, thus delivering a consistent and superior user experience with strong and secure authentication across channels.

Moreover, software vendors are providing various development kits in the market, allowing technology providers to provide advanced contactless biometrics software for their hardware. For instance, in January 2020, FaceFirst, launched a Software Development Kit (SDK) for developers of identity verification products to integrate advanced facial recognition into their systems. The SDK works offline or online, runs in a docker container, and supports Linux OS to enable easy integration into any IoT device.

Vendors are focusing on agreements, acquisitions, and new product development in order to maintain their position in the market. For instance, in June 2019, HID Global announced an agreement to acquire an identity solutions business of De La Rue. The acquisition helped the former company to strengthen its position in government identification market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/contactless-biometrics-technology-market

Further key findings from the report suggest:

  • Software segment is anticipated to register considerable growth over the forecast period, as it plays a significant role in ensuring the interoperability and compatibility of contactless biometric devices
  • Iris segment is expected to register highest growth rate over the forecast period. Iris biometrics identification is highly scalable and also ensures hygiene factors, which is expected to drive the segment growth
  • Banking and finance segment is anticipated to register a phenomenal growth from 2020 to 2027. Rising demand for secured digital banking services and need to offer enhanced customer experience is driving the segment growth
  • Asia Pacific is anticipated to register the highest growth rate over the forecast period, as countries in the region have started standardizing their security systems by implementing contactless biometrics solutions to enhance border security

Edge Artificial Intelligence Chips Market Size Worth $9.5 Billion By 2027

The global edge artificial intelligence chips market size is expected to reach USD 9.5 billion by 2027, according to a new report by Grand View Research, Inc. The market is anticipated to register a CAGR of 21.3% from 2020 to 2027. Semiconductor companies are experiencing high demand for their existing chips with hardware serving as a differentiator in AI. Also, these companies are developing workload-specific (training and inference) AI accelerators. For instance, Apple has implemented a neural engine in its A11 Bionic chip’s processor to speed-up the third-party applications. The market is growing rapidly with the rising implementations of edge-based AI in smartphones and autonomous vehicles.

Demand for more efficient processors due to increasing data complexity and need for local data processing is encouraging the semiconductors industry to adopt edge-based artificial intelligence chips. With the rise in AI applications ranging from consumer devices to enterprise devices, adoption of edge AI-supported chips has been noted considerably. The market for consumer devices is much larger than that for enterprise devices because the enterprise edge-based AI chip market is newer. For instance, in July 2017, the first enterprise edge AI chip, named Neural Compute Stick (NCS), was introduced by the Intel Corporation.

Edge computing has been proven as the best choice for the inference function. Since the AI algorithm handles less amount of data and is required to generate responses more rapidly with inference, therefore, artificial intelligence at the edge is used for most data inference use-cases. For instance, self-driving cars and medical applications cannot transmit images to the cloud for processing as they require responses in a shorter period. With the rise in IoT devices, such as connected cars, demand for edge AI chips is anticipated to grow.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/edge-artificial-intelligence-chips-market

Further key findings from the report suggest:

  • Considerable surge in connected cars and other IoT devices will create wide potential for manufacturers in market
  • Prominent companies, such as Alphabet Inc., are significantly involved in the integration of new AI capabilities, such as natural language dialogue, storytelling in their AI chips
  • Market players are focusing on providing advanced AI chips for edge computing which provides advanced features, such as visual intelligence, for better recognition and differentiation of locations, spaces, and objects
  • Market participants are undertaking strategic initiatives, including partnerships and mergers & acquisitions of tech-based startups providing innovative products to expand their outreach in the market
  • Some of the key companies areAdvanced Micro Devices, Inc.; Alphabet, Inc.; Intel Corp.; Qualcomm Technologies, Inc.; Apple, Inc.; Mythic Ltd.; Arm Ltd.; Samsung Electronics Co., Ltd.; NVIDIA Corp.; HiSilicon (Shanghai) Technologies Co., Ltd.; and Xilinx, Inc.

Artificial Intelligence in Telecommunication Market Worth $9.3 Billion By 2027

The global artificial intelligence in telecommunication market size is expected to reach USD 9.3 billion by 2027, according to a new report by Grand View Research, Inc. The market is anticipated to register a CAGR of 38.4% from 2020 to 2027.

Communication Service Providers (CSPs) need to bring the intelligence in their system optimization, planning, and operations to address the increasing complexities in communication networks caused due to the deployment of new technology paradigms, such as Network Function Virtualization (NFV) and Software-Defined Wide-Area Networking (SD-WAN). Therefore, the telecommunications industry is exploring and introducing AI to improve network efficiency and customer experience.

The telecommunication industry has leveraged technologies, such as cloud computing, big data analytics, and deep learning, to fulfill consumer demands of multimedia services and network security. Also, the intellectualization of communication networks has become possible with the invention of technologies of service-aware network systems and deep packet inspection. Researchers in the industry are tapping into artificial intelligence-based techniques to optimize network architecture & management, and to enable more autonomous operations.

Furthermore, the next-generation wireless networks are anticipated to evolve into more complex system architectures due to the diversified service requirements and heterogeneity in devices, system architectures, and applications. Artificial intelligence has renewed interest in the telecom industry due to the rising complexity of network technology. Potential AI-based use-cases in communication networks include network operation monitoring & management, fraud mitigation, predictive maintenance, cybersecurity, and virtual assistants for marketing and customer service. However, network operation monitoring & management remains the top use-case in the telecom industry as several communications service providers have adopted AI approaches to address the need for communication automation and agility.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-telecommunication-market

Further key findings from the study suggest:

  • Improving customer experience is one of the major factors driving the growth of the market since chatbots deployed for customer service have fueled the business earnings adequately
  • Machine learning approaches are beginning to emerge in the telecommunication domain to address the challenges of virtualization
  • AI-supported network-centric applications include anomaly detection for maintenance and provisioning, performance monitoring, alert suppression, automated resolution of a trouble ticket, network faults prediction, and network capacity planning or congestion prediction
  • Key companies in the market areIBM Corp.; Microsoft Corp.; Intel Corp.; Google, Inc.; AT&T Intellectual Property; Cisco Systems; Nuance Communications, Inc.; Evolv Technology Solutions, Inc.; H2O.ai; Infosys Ltd.; Salesforce.com, Inc.; and NVIDIA Corp.

Arrhythmia Monitoring Devices Market Worth $8.41 Billion By 2025

The global arrhythmia monitoring devices market size is expected to reach USD 8.41 billion in 2025 with a CAGR of 6.8% during the forecast period, according to a new report by Grand View Research, Inc. Continuous R&D activities in the field of cardiac monitoring are leading to technological expansion. This, in turn, is positively influencing the growth of the arrhythmia monitoring devices market. Wearable diagnostic patch by iRhythm Technologies, Inc., Zio, has led to symptomatic arrhythmia monitoring, which is superior in comparison to conventional Holter monitors.

Big pharma and medical device companies are heavily investing in R&D to perform a detailed mapping of cardiac arrhythmia. In February 2018, Medtronic received FDA clearance for the first non-invasive cardiac mapping system, CardioInsight. It includes wearable 252-electrode sensor vest that creates 3D electroanatomic maps of heart by combining data from a cardiac computed tomography scan with ECG signals collected from the chest region.

In addition to these technologies, emergence and advancements in mobile cardiac telemetry are leading to further progress of the overall market. In October 2017, Abbott received FDA clearance for Confirm Rx, a smartphone-compatible implantable cardiac monitor indicated for arrhythmia diagnosis. Boston Scientific announced its FDA approval for Resonate, a line of cardiac resynchronization therapy defibrillator and cardioverter defibrillator systems for the cardiac management.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/arrhythmia-monitoring-devices-market

Further Key Findings from the Study Suggest:

  • The arrhythmia monitoring devices market is highly competitive and is rapidly evolving with numerous potential market players
  • Holter monitors dominated the market in terms of revenue in 2017. On the other hand, mobile cardiac telemetry is expected to witness the fastest growth rate during the forecast period
  • Atrial fibrillation dominated the market in terms of revenue in 2017. The growth in the number of untreated cases of arrhythmias are leading to increasing need for advanced cardiac monitoring devices
  • Heightened adoption of sophisticated technologies has led to the expansion of the market. Kardia Mobile by AliveCor captures ECG in 30 seconds projecting the heart rhythm for conditions such as atrial fibrillation
  • The hospitals and clinics segment held the largest share in the market in 2017. On the other hand, diagnostic centers are likely to experience the fastest growth over the forecast period
  • North America commanded the leading share in the market in 2017 due to faster regulatory approvals for innovative devices and procedures
  • AliveCor, Inc.; Applied Cardiac Systems; BioTelemetry, Inc.; BIOTRONIK; Fukuda Denshi Co., Ltd.; GE Healthcare; iRhythm; Medi-Lynx; St. Jude Medical (Abbott); Medtronic; Nihon Kohden Corporation; Nuubo; and Spacelabs Healthcare are some of the key players operating in this market.

Clinical Oncology NGS Market Size Worth $1.5 Billion By 2025

The global clinical oncology next generation sequencing (NGS) market size is expected to reach USD 1.5 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 13.2% over the forecast period. Rise in demand for personalized medicine, coupled with growth in next generation sequencing technology, is anticipated to accelerate the growth of NGS technology in clinical diagnostics.

Owing to the fact that next generation sequencing offers several advantages such as sensitivity, accuracy, and speed, this technology is anticipated to drive the oncology clinical diagnostics market. Furthermore, next generation sequencing aids in the assessment of multiple genes in a single assay, thereby eliminating the need to order several tests for determination of underlying mutation.

North America held the dominant share in the global the market for clinical oncology NGS in 2018 owing to increased focus of government bodies on cancer treatment, rise in healthcare expenditure, and presence of adequate infrastructure in the healthcare industry. Asia Pacific is expected to be the fastest-growing regional market throughout the forecast period majorly due to continuous reforms in the healthcare and pharmaceutical industries in the region. Presence of untapped markets in emerging economies in the region will also benefit regional growth. 

Click the link below:
https://www.grandviewresearch.com/industry-analysis/clinical-oncology-next-generation-sequencing-ngs-market

Further key findings from the report suggest:

  • By technology, targeted sequencing and resequencing held the largest share in 2018 owing to frequent usage in cancer diagnostics. On the other hand, whole-genome sequencing (WGS) is expected to grow at a lucrative rate owing to wide-scale applications and rising demand for the technique
  • Based on application, companion diagnostics is anticipated to witness the fastest growth as a consequence of presence of a substantial number of pharmaceutical and diagnostic developers collaborating to commercialize the products. These participants are focused on extensive R&D in companion diagnostics to obtaining regulatory approval for novel assays combined with pharmaceuticals
  • On the basis of end use, the clinics segment will expand at a significant growth rate thanks to increase in feasibility for the use of next generation sequencing technology
  • North America occupied the largest share owing to increased focus of government bodies on cancer treatment, rise in healthcare expenditure, and presence of adequate healthcare infrastructure
  • Asia Pacific is expected to grow at the fastest rate due to continuous reforms in the healthcare and pharmaceutical sectors, accompanied by improvement in reimbursement policies
  • Illumina, Inc.; Thermo Fisher Scientific; F. Hoffmann-La Roche Ltd; Agilent Technologies; Myriad Genetics; Beijing Genomics Institute (BGI); Perkin Elmer; Foundation Medicine; Pacific Bioscience; Oxford Nanopore Technologies Ltd; Paradigm Diagnostics; Caris Life Sciences; Partek, Inc.; Eurofins Scientific S.E; and Qiagen N.V. are some of the key participants operating in this market. These participants are engaged in new product development and strategic alliances for enhancing their competitive footprint in the market.

Myasthenia Gravis Treatment Market Size Worth $2.06 Billion By 2026

The global myasthenia gravis treatment market size is expected to reach USD 2.06 billion by 2026 at a CAGR of 7.5% through the forecast period, according to a new report by Grand View Research. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/myasthenia-gravis-mg-treatment-market

Further Key Findings From the Study Suggest:

  • Medications are expected to obtain the largest market share in the treatment segment. This can be attributed to the high adoption of immunotherapies and the recent approval of promising drugs.
  • Currently, no cure is available for myasthenia gravis, however patients can be treated with medications and surgery for the management of the symptoms.
  • North America is likely to dominate the MG treatment market due high healthcare expenditure and favorable reimbursement scenario
  • The Asia Pacific region is expected to grow at the highest CAGR over the forecast period due to improving healthcare infrastructure and increasing disposable income in the region.
  • Some of the major companies operating in the market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., and Shire plc.

Acute Repetitive Seizures Market Size Worth $3.19 Billion By 2025

The global acute repetitive seizures market size is expected to reach USD 3.19 billion by 2025, according to a new report by Grand View Research, Inc. The report also states that the market will expand at a strong CAGR of 47.8% during the forecast period. Rise in the number of initiatives to increase awareness about epilepsy is the major factor driving the market.

The market is currently led by generic drugs which mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only approved drug for use in U.S. and buccal midazolam in the European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (buccal, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual), and progesterone are majorly used off label. The market is expected to be consolidated with a few major companies and a high market share.

Furthermore, in an attempt to curb healthcare expenditure, governments are making continuous efforts to reduce hospital stays and on-site treatment costs via outpatient care models, such as clinic and home healthcare. Emerging economies like India and China, are increasingly implementing such healthcare reform, which is expected to propel the growth of acute repetitive seizures market.

There are several routes of drug administration; out of which, the nasal route is the most preferred over others, such as buccal, rectal, and parenteral. The buccal route is preferred by caregivers and parents for children suffering from pediatric seizures since medication can be administered even outside the hospital.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/acute-repetitive-seizures-market

Further key findings from the study suggest:

  • Global acute repetitive seizures market size was estimated at USD 140.5 million in 2017 and is expected to register a CAGR of 47.8% over the forecast period
  • Diastat rectal gel was the dominant product segment in 2017 due to the efficacy of the route of administration and affordability of the product
  • USL-261 is expected to witness a lucrative CAGR over the forecast period. USL-21 has an edge over the other drugs owing to its superior clinical profile and positive phase III results
  • North America held the largest share in 2017 due to factors, such as growing initiatives for raising awareness about epilepsy and seizures
  • Germany is anticipated to witness lucrative growth over the next decade owing to technological advancements in scientific, clinical, and medical fields
  • Some of the key companies in the market are UCB S.A.; Neurelis, Inc.; and Alexza Pharmaceuticals, Inc. These companies are likely to dominate the market and gain maximum share over the forecast period